Reuters logo
4 个月前
BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140
2017年4月4日 / 晚上6点03分 / 4 个月前

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

1 分钟阅读

April 4 (Reuters) - Cyclacel Pharmaceuticals Inc

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

* Cyclacel -study concluded cyc140 is a selective plk1 inhibitor which preferentially induces growth inhibition and cell death in malignant versus non-malignant cells Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below